CMCarsten Magnus

Carsten Magnus

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Carsten Magnus has a total of 761 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The Open Hand Initiative: Facilitating the Use of Real‐World Evidence in Regulatory Submissions Through Collaboration and Transparency

    by Elodie Baumfeld Andre, Matthew Gee, Carsten Magnus, Stephanie Greeman, Pipper White, Maryellen de Mars, Brad Spring

    Real‐world data (RWD) collected to generate real‐world evidence (RWE) holds promise for expediting patient and healthcare provider access to new in vitro diagnostics (IVDs) by serving as evidence to demonstrate test performance or utility. However, uncertainties remain for IVD developers (device manufacturers), regulators, and other healthcare stakeholders on the specifics of collecting fit‐for‐purpose RWD and using RWE for regulatory decision‐making. We report on a unique approach to medical device regulatory review called the Open Hand Initiative, by which the US Food and Drug Administration (FDA) and device manufacturers collaborate to ensure the appropriate use of RWD/RWE to support regulatory decision‐making. Normally, regulatory submission interactions are confidential; in the Open Hand approach, device manufacturers share high‐level learnings from pre‐submission interactions to advance the use of reliable and relevant RWD/RWE for regulatory decision‐making. In a pilot study, the Open Hand approach was applied to pre‐submission interactions regarding the use of RWD/RWE for transition of SARS‐CoV‐2 serology IVDs with Emergency Use Authorization (EUA) to full market authorization. Participants in the pilot agreed that the candid discussions were key to identifying barriers to efficient, timely, and robust RWE generation for IVD premarket submissions. The pilot also led to valuable lessons learned around current regulatory requirements for RWE, SARS‐CoV‐2 testing complexities, and the impact that the rapidly evolving COVID‐19 pandemic had on RWD availability and quality. The Open Hand Initiative can be applied more broadly to guide device manufacturers in collecting high‐quality RWD to generate RWE for premarket applications.


  • Open Access

    Assessing bnAb potency in the context of HIV-1 Envelope conformational plasticity

    by Caio Foulkes, Nikolas Friedrich, Branislav Ivan, Emanuel Stiegeler, Carsten Magnus, Daniel Schmidt, Umut Karakus, Jacqueline Weber, Huldrych F. Günthard, Chloé Pasin, et al.

    The ability of broadly neutralizing antibodies (bnAbs) to interact with the closed, pre-fusion HIV-1 envelope (Env) trimer distinguishes them from weakly neutralizing antibodies (weak-nAbs) that depend on trimer opening to bind. Comparative analysis of neutralization data from the CATNAP database revealed a nuanced relationship between bnAb activity and Env conformational plasticity, with substantial epitope-specific variation of bnAb potency ranging from increased to decreased activity against open, neutralization-sensitive Env. To systematically investigate the impact of Env conformational dynamics on bnAb potency we screened 126 JR-CSF point mutants for generalized neutralization sensitivity to weak-nAbs and plasma from people with chronic HIV-1 infection. 23 mutations at highly conserved sites resulted in neutralization phenotype with high Tier 1 sensitivity, which was associated with destabilization of the closed, prefusion conformation. Including 19 of these mutants into a Sensitivity Env mutant panel (SENSE-19), we classified bnAbs according to potency variations in response to trimer opening. To verify that these sensitivity patterns are independent of the in vitro assay system, replication-competent SENSE-19 mutant viruses were tested on primary CD4 T cells. While loss of potency on SENSE-19 was registered for bnAbs recognizing quaternary epitopes on pre-triggered Env, structural destabilization benefitted MPER bnAbs and other inhibitors known to have post-CD4 attachment neutralization activity. Importantly, for certain bnAbs targeting CD4bs, V3-glycan and interface epitopes, particularly low potency variation was noted, suggesting that Env conformational tolerance can be achieved but is not the rule. In summary, SENSE-19 screens revealed distinct Env flexibility tolerance levels between bnAb types that provide mechanistic insights in their function and broaden current neutralization breadth assessments. Author summary Consistently high potency and neutralizing breadth against genetically divergent strains circulating worldwide are central to the applicability of HIV-1 broadly neutralizing antibodies (bnAbs) for prevention and therapy. The trimeric Envelope protein complex on these viruses is the target for nAbs and because of its inherent flexibility can be presented in different shapes. However, the activity of nAbs depends to different degree on the presentation of certain shapes, limiting their potency and breadth. Here we assemble a virus panel that can be used to estimate this dependence, enabling the identification of bnAbs tolerating the presentation of different shapes.

  • Open Access

    IFITM3 incorporation sensitizes influenza A virus to antibody-mediated neutralization

    by Caroline Lanz, Michael Schotsaert, Carsten Magnus, Umut Karakus, Annika Hunziker, Milagros Sempere Borau, Carles Martínez-Romero, Eva E. Spieler, Sira C. Günther, Eva Moritz, et al.

    The disease severity of influenza is highly variable in humans, and one genetic determinant behind these differences is the IFITM3 gene. As an effector of the interferon response, IFITM3 potently blocks cytosolic entry of influenza A virus (IAV). Here, we reveal a novel level of inhibition by IFITM3 in vivo: We show that incorporation of IFITM3 into IAV particles competes with incorporation of viral hemagglutinin (HA). Decreased virion HA levels did not reduce infectivity, suggesting that high HA density on IAV virions may be an antagonistic strategy used by the virus to prevent direct inhibition. However, we found that IFITM3-mediated reduction in HA content sensitizes IAV to antibody-mediated neutralization. Mathematical modeling predicted that this effect decreases and delays peak IAV titers, and we show that, indeed, IFITM3-mediated sensitization of IAV to antibody-mediated neutralization impacts infection outcome in an in vivo mouse model. Overall, our data describe a previously unappreciated interplay between the innate effector IFITM3 and the adaptive immune response.


  • Open Access

    Heterologous arenavirus vector prime-boost overrules self-tolerance for efficient tumor-specific CD8 T cell attack

    by Weldy V. Bonilla, Nicole Kirchhammer, Anna-Friederike Marx, Sandra M. Kallert, Magdalena A. Krzyzaniak, Min Lu, Stéphanie Darbre, Sarah Schmidt, Josipa Raguz, Ursula Berka, et al.


  • Open Access

    Profiling host ANP32A splicing landscapes to predict influenza A virus polymerase adaptation

    by Patricia Domingues, Davide Eletto, Carsten Magnus, Hannah L. Turkington, Stefan Schmutz, Osvaldo Zagordi, Matthias Lenk, Martin Beer, Silke Stertz, Benjamin G. Hale

    Species’ differences in cellular factors limit avian influenza A virus (IAV) zoonoses and human pandemics. The IAV polymerase, vPol, harbors evolutionary sites to overcome restriction and determines virulence. Here, we establish host ANP32A as a critical driver of selection, and identify host-specific ANP32A splicing landscapes that predict viral evolution. We find that avian species differentially express three ANP32A isoforms diverging in a vPol-promoting insert. ANP32As with shorter inserts interact poorly with vPol, are compromised in supporting avian-like IAV replication, and drive selection of mammalian-adaptive vPol sequences with distinct kinetics. By integrating selection data with multi-species ANP32A splice variant profiling, we develop a mathematical model to predict avian species potentially driving (swallow, magpie) or maintaining (goose, swan) mammalian-adaptive vPol signatures. Supporting these predictions, surveillance data confirm enrichment of several mammalian-adaptive vPol substitutions in magpie IAVs. Profiling host ANP32A splicing could enhance surveillance and eradication efforts against IAVs with pandemic potential.


  • Open Access

    Phenotypic deficits in the HIV-1 envelope are associated with the maturation of a V2-directed broadly neutralizing antibody lineage

    by Lucia Reh, Carsten Magnus, Claus Kadelka, Denise Kühnert, Therese Uhr, Jacqueline Weber, Lynn Morris, Penny L Moore, Alexandra Trkola

    Broadly neutralizing antibodies (bnAbs) to HIV-1 can evolve after years of an iterative process of virus escape and antibody adaptation that HIV-1 vaccine design seeks to mimic. To enable this, properties that render HIV-1 envelopes (Env) capable of eliciting bnAb responses need to be defined. Here, we followed the evolution of the V2 apex directed bnAb lineage VRC26 in the HIV-1 subtype C superinfected donor CAP256 to investigate the phenotypic changes of the virus populations circulating before and during the early phases of bnAb induction. Longitudinal viruses that evolved from the VRC26-resistant primary infecting (PI) virus, the VRC26-sensitive superinfecting (SU) virus and ensuing PI-SU recombinants revealed substantial phenotypic changes in Env, with a switch in Env properties coinciding with early resistance to VRC26. Decreased sensitivity of SU-like viruses to VRC26 was linked with reduced infectivity, altered entry kinetics and lower sensitivity to neutralization after CD4 attachment. VRC26 maintained neutralization activity against cell-associated CAP256 virus, indicating that escape through the cell-cell transmission route is not a dominant escape pathway. Reduced fitness of the early escape variants and sustained sensitivity in cell-cell transmission are both features that limit virus replication, thereby impeding rapid escape. This supports a scenario where VRC26 allowed only partial viral escape for a prolonged period, possibly increasing the time window for bnAb maturation. Collectively, our data highlight the phenotypic plasticity of the HIV-1 Env in evading bnAb pressure and the need to consider phenotypic traits when selecting and designing Env immunogens. Combinations of Env variants with differential phenotypic patterns and bnAb sensitivity, as we describe here for CAP256, may maximize the potential for inducing bnAb responses by vaccination. HIV-1 infected individuals rarely develop broadly neutralizing antibodies (bnAbs) that inhibit diverse HIV-1 subtypes. As activity against the majority of HIV-1 isolates is necessary for effective immunization against HIV-1, current vaccine development seeks to generate regimens that evoke bnAb responses. Delineating why bnAbs develop in certain cases of HIV-1 infection is thus of pivotal importance. In all infected individuals, HIV-1 inevitably escapes neutralizing antibody pressure and even the most potent bnAbs cannot clear the infection from the patient where they emerged. Yet, exactly this continuous interplay between virus escape and antibody maturation is believed to be crucial in the evolution of bnAbs, with virus escape variants containing modified HIV-1 envelope (Env) proteins, the target of neutralizing antibodies that in some cases can direct the immune response towards breadth. Identifying features of naturally occurring Env proteins that are involved in evoking bnAb responses is thus of high interest. Here, we analyzed Env features of virus isolates from donor CAP256 who developed the potent V2 apex bnAb VRC26, one of the current lead bnAbs for HIV-1 therapy and vaccine development. We show that the viral escape variants that appeared soon after the onset of the VRC26 response had highly altered Env protein properties that, in addition to reducing sensitivity to VRC26, affected their capacity to infect and altered entry dynamics. This highlights constrained viral escape pathways, but also features of VRC26 that may have prevented rapid escape. We postulate that this may have resulted in a prolonged circulation of partially VRC26 sensitive viruses, hence allowing the bnAb response to mature.


  • Open Access

    The influence of phylodynamic model specifications on parameter estimates of the Zika virus epidemic

    by Veronika Boskova, Tanja Stadler, Carsten Magnus

    Each new virus introduced into the human population could potentially spread and cause a worldwide epidemic. Thus, early quantification of epidemic spread is crucial. Real-time sequencing followed by Bayesian phylodynamic analysis has proven to be extremely informative in this respect. Bayesian phylodynamic analyses require a model to be chosen and prior distributions on model parameters to be specified. We study here how choices regarding the tree prior influence quantification of epidemic spread in an emerging epidemic by focusing on estimates of the parameters clock rate, tree height, and reproductive number in the currently ongoing Zika virus epidemic in the Americas. While parameter estimates are quite robust to reasonable variations in the model settings when studying the complete data set, it is impossible to obtain unequivocal estimates when reducing the data to local Zika epidemics in Brazil and Florida, USA. Beyond the empirical insights, this study highlights the conceptual differences between the so-called birth–death and coalescent tree priors: while sequence sampling times alone can strongly inform the tree height and reproductive number under a birth–death model, the coalescent tree height prior is typically only slightly influenced by this information. Such conceptual differences together with non-trivial interactions of different priors complicate proper interpretation of empirical results. Overall, our findings indicate that phylodynamic analyses of early viral spread data must be carried out with care as data sets may not necessarily be informative enough yet to provide estimates robust to prior settings. It is necessary to do a robustness check of these data sets by scanning several models and prior distributions. Only if the posterior distributions are robust to reasonable changes of the prior distribution, the parameter estimates can be trusted. Such robustness tests will help making real-time phylodynamic analyses of spreading epidemic more reliable in the future.


  • Open Access

    Taming the BEAST—A Community Teaching Material Resource for BEAST 2

    by Joëlle Barido-Sottani, Veronika Bošková, Louis Du Plessis, Denise Kühnert, Carsten Magnus, Venelin Mitov, Nicola F. Müller, Jūlija PečErska, David A. Rasmussen, Chi Zhang, et al.

    Phylogenetics and phylodynamics are central topics in modern evolutionary biology. Phylogenetic methods reconstruct the evolutionary relationships among organisms, whereas phylodynamic approaches reveal the underlying diversification processes that lead to the observed relationships. These two fields have many practical applications in disciplines as diverse as epidemiology, developmental biology, palaeontology, ecology, and linguistics. The combination of increasingly large genetic data sets and increases in computing power is facilitating the development of more sophisticated phylogenetic and phylodynamic methods. Big data sets allow us to answer complex questions. However, since the required analyses are highly specific to the particular data set and question, a black-box method is not sufficient anymore. Instead, biologists are required to be actively involved with modeling decisions during data analysis. The modular design of the Bayesian phylogenetic software package BEAST 2 enables, and in fact enforces, this involvement. At the same time, the modular design enables computational biology groups to develop new methods at a rapid rate. A thorough understanding of the models and algorithms used by inference software is a critical prerequisite for successful hypothesis formulation and assessment. In particular, there is a need for more readily available resources aimed at helping interested scientists equip themselves with the skills to confidently use cutting-edge phylogenetic analysis software. These resources will also benefit researchers who do not have access to similar courses or training at their home institutions. Here, we introduce the “Taming the Beast” (https://taming-the-beast.github.io/) resource, which was developed as part of a workshop series bearing the same name, to facilitate the usage of the Bayesian phylogenetic software package BEAST 2.


  • Open Access

    Predicting HIV-1 transmission and antibody neutralization efficacy in vivo from stoichiometric parameters

    by Oliver F. Brandenberg, Carsten Magnus, Peter Rusert, Huldrych F. Günthard, Roland R. Regoes, Alexandra Trkola

    The potential of broadly neutralizing antibodies targeting the HIV-1 envelope trimer to prevent HIV-1 transmission has opened new avenues for therapies and vaccines. However, their implementation remains challenging and would profit from a deepened mechanistic understanding of HIV-antibody interactions and the mucosal transmission process. In this study we experimentally determined stoichiometric parameters of the HIV-1 trimer-antibody interaction, confirming that binding of one antibody is sufficient for trimer neutralization. This defines numerical requirements for HIV-1 virion neutralization and thereby enables mathematical modelling of in vitro and in vivo antibody neutralization efficacy. The model we developed accurately predicts antibody efficacy in animal passive immunization studies and provides estimates for protective mucosal antibody concentrations. Furthermore, we derive estimates of the probability for a single virion to start host infection and the risks of male-to-female HIV-1 transmission per sexual intercourse. Our work thereby delivers comprehensive quantitative insights into both the molecular principles governing HIV-antibody interactions and the initial steps of mucosal HIV-1 transmission. These insights, alongside the underlying, adaptable modelling framework presented here, will be valuable for supporting in silico pre-trial planning and post-hoc evaluation of HIV-1 vaccination or antibody treatment trials. Successful solicitation of the potential of neutralizing antibodies for HIV-1 prevention will require a deepened understanding of HIV-1 transmission and antibody neutralization. In this study, we experimentally determined molecular parameters of the HIV-1-antibody interaction, and subsequently used this knowledge to devise a mathematical model of HIV-1 infection and antibody neutralization in vivo. First, we experimentally confirmed that binding of one antibody per HIV-1 envelope trimer is sufficient for trimer neutralization. This finding, in combination with the number of trimers per HIV-1 virion, the number of trimers required for virus entry, and the affinity of antibody-trimer binding, enabled precise modelling of HIV-1 antibody neutralization. We employed our model for a post-hoc analysis of non-human primate infection studies, thereby obtaining estimates of HIV-1 neutralization in vivo and the probability for a single HIV-1 virion to initiate host infection. We further modelled HIV-1 infection and antibody neutralization during male-to-female transmission in the human host, which delivered estimates for the likelihood of HIV-1 transmission per sexual act and predictions of protective mucosal antibody concentrations. The quantitative insights into HIV-1 infection and antibody neutralization derived here, spanning from the molecular to the systemic level, contribute to a refined understanding of HIV-1 transmission and may prove useful for pre-study planning or post-hoc analyses of HIV-1 clinical trials and vaccine studies.


  • Open Access

    Delineating CD4 dependency of HIV-1: Adaptation to infect low level CD4 expressing target cells widens cellular tropism but severely impacts on envelope functionality

    by David Beauparlant, Peter Rusert, Carsten Magnus, Claus Kadelka, Jacqueline Weber, Therese Uhr, Osvaldo Zagordi, Corinna Oberle, Maria J. Duenas-Decamp, Paul R. Clapham, et al.

    A hallmark of HIV-1 infection is the continuously declining number of the virus’ predominant target cells, activated CD4+ T cells. With diminishing CD4+ T cell levels, the capacity to utilize alternate cell types and receptors, including cells that express low CD4 receptor levels such as macrophages, thus becomes crucial. To explore evolutionary paths that allow HIV-1 to acquire a wider host cell range by infecting cells with lower CD4 levels, we dissected the evolution of the envelope-CD4 interaction under in vitro culture conditions that mimicked the decline of CD4high target cells, using a prototypic subtype B, R5-tropic strain. Adaptation to CD4low targets proved to severely alter envelope functions including trimer opening as indicated by a higher affinity to CD4 and loss in shielding against neutralizing antibodies. We observed a strikingly decreased infectivity on CD4high target cells, but sustained infectivity on CD4low targets, including macrophages. Intriguingly, the adaptation to CD4low targets altered the kinetic of the entry process, leading to rapid CD4 engagement and an extended transition time between CD4 and CCR5 binding during entry. This phenotype was also observed for certain central nervous system (CNS) derived macrophage-tropic viruses, highlighting that the functional perturbation we defined upon in vitro adaptation to CD4low targets occurs in vivo. Collectively, our findings suggest that CD4low adapted envelopes may exhibit severe deficiencies in entry fitness and shielding early in their evolution. Considering this, adaptation to CD4low targets may preferentially occur in a sheltered and immune-privileged environment such as the CNS to allow fitness restoring compensatory mutations to occur. Untreated HIV-1 infection leads to a gradual depletion of CD4+ T cells forcing the virus to continuously adapt to an ever-decreasing number of suitable target cells. Our data based on experiments in a highly controlled in vitro setting describe one avenue of envelope adaptation that allows the virus to infect target cells expressing low amounts of CD4 such as macrophages. Analysis of the functional envelope phenotypes associated with adaptation of the virus to infect target cells expressing low levels of CD4 highlighted altered entry kinetics of the virus. These alterations resulted in extended exposure of CD4-induced neutralization sensitive epitopes in combination with an increased sensitivity to neutralizing antibodies targeting the CD4 binding site and the V3 loop. Interestingly, a similar phenotype was observed for macrophage-tropic HIV-1 isolates derived from the central nervous system (CNS) of infected individuals raising the possibility that the immune-privileged CNS may favor the development of macrophage-tropic / low CD4 level utilizing envelope variants.